Ironwood
`
`February 11 , 2013
`
`'
`
`Ironwood Pharmaceuticals Promotes Dr. Mark Currie to Senior Vice President, Chief
`Scientific Officer, and President of R&D
`
`CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the promotion of
`Mark Currie, Ph.D. to senior vice president, chief scientific officer (CSO), and president of research and development (R&D).
`
`"Mark's outstanding contributions to Ironwood,
`including his expertise, leadership and superb
`judgment, are invaluable as we move our R&D
`efforts forward, growing our active pipeline and
`expanding our development efforts globally on
`behalf of our shareholders and the patients we
`aim to serve," said Peter Hecht, chief executive
`officer of Ironwood. "Mark's pioneering
`academic research on the guanylate cyclase-C
`(GC-C) pathway, including his discovery of the
`natural hormones that activate GC-C,
`established the foundation for the discovery of
`linaclotide by Ironwood scientists, and he has
`led every aspect of linaclotide's development
`and regulatory review, resulting in LINZ ESSTM
`(linaclotide) being the first and only GC - C
`agonist approved in the U.S., Constella®
`(linaclotide) being the first therapy approved
`for patients w ith IBS-C in Europe, and
`linaclotide development programs advancing in
`Japan and China."
`
`Mark Currie, Ph.D., senior vice president, CSO, and president of R&D of Ironwood
`Dr. Currie has led the company's R&D efforts
`Pharmaceuticals, Inc. (Photo: Business Wire)
`since he joined Ironwood in 2002 and previously served as senior vice president, R&D and CSO at Ironwood . Prior to that, he
`directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor Inc.
`Previously, Dr. Currie initiated, built, and led discovery pharmacology and also served as director of arthritis and inflammation
`at Monsanto Company. Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell
`biology from the Bowman-Gray School of Medicine of Wake Forest University.
`
`About Ironwood Pharmaceuticals
`
`Ironwood Pharmaceuticals (NASDAQ : IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of
`great drugmaking . Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.
`
`Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130211005762/en/
`
`Ironwood Pharmaceuticals, Inc.
`Media Relations
`Lisa Buffington, 617-374-5103
`Vice President, Corporate Communications
`lbuffington@ironwoodpharma.com
`or
`Investor Relations
`Meredith Kaya, 617-37 4-5082
`Associate Director, Investor Relations
`mkaya@ironwoodpharma.com
`
`Bausch Health Ireland Exhibit 2013, Page 1 of2
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`

`

`Source: Ironwood Pharmaceuticals, Inc.
`
`News Provided by Acquire Media
`
`Bausch Health Ireland Exhibit 2013, Page 2 of2
`Mylan v. Bausch Health Ireland - IPR2022-00722
`
`